Report: Gardasil cost-effective for girls, young women

Gardasil, Merck & Co.'s human papillomavirus vaccine designed to prevent cervical cancer, is cost-effective only for preadolescent girls and women as old as 21, according to an economic analysis by Harvard University researchers. The findings support the CDC's recommendation to routinely immunize 11- and 12-year-old girls before they become sexually active.

View Full Article in:

USA Today · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC